Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
While it did not affect the primary endpoint of major adverse cardiovascular events, targeted vitamin D supplementation was linked to reduced risk for recurrent heart attack, according to results of ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Fantasy football relevant injuries and their impact, weather reports and game previews. Plus, Ciely's Week 11 player rankings ...
Propellants in asthma inhalers produce greenhouse gas emissions equivalent to driving 200 miles, yet most healthcare systems ...
Florida Supplement Brand Expands ‘Gelatin Trick’ Coverage With Clinically Referenced Morning, Afternoon, and Evening Recipes Supporting Healthy Metabolism ...
New analysis finds cycling, basketball, and football lead the nation in ER-treated sports injuries Cycling alone sent more ...
PDS Biotechnology Corporation (NASDAQ: PDSB) Q3 2025 Earnings Call Transcript November 13, 2025 ...
Coinbase plans to host roughly one token sale per month going forward, creating a structured, recurring schedule for new digital asset launches.
Introduction Ascertaining the cause of sudden death is often difficult, even in patients with a history of heart disease.
Three decades of climate summits and the planet is still getting hotter. We know these meetings aren’t working well enough, ...
Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Q3, 2025 Earnings Conference Call. An audio recording of this webcast will be available shortly after the call today on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback